20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecular profiling for lung cancer.

In a special episode of the new Cancer Letter Podcast, Suresh S. Ramalingam, a lung cancer expert, executive director of Winship Cancer Institute of Emory University, and editor-in-chief of the journal Cancer, moderates a panel of people who played a role in the discovery of the EGFR mutation in lung cancer. Listen here.